Michael Wiederhorn
Stock Analyst at Oppenheimer
(3.69)
# 756
Out of 5,152 analysts
144
Total ratings
56.74%
Success rate
4.53%
Average return
Main Sectors:
Stocks Rated by Michael Wiederhorn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PACS PACS Group | Maintains: Outperform | $40 → $42 | $36.35 | +15.54% | 4 | Mar 4, 2026 | |
| TDOC Teladoc Health | Maintains: Outperform | $12 → $7 | $5.13 | +36.45% | 12 | Mar 3, 2026 | |
| EVH Evolent Health | Maintains: Outperform | $12 → $6 | $3.55 | +69.01% | 2 | Mar 2, 2026 | |
| CHE Chemed | Maintains: Outperform | $580 → $500 | $410.99 | +21.66% | 14 | Feb 27, 2026 | |
| UNH UnitedHealth Group | Maintains: Outperform | $415 → $385 | $291.96 | +31.87% | 18 | Jan 28, 2026 | |
| HCA HCA Healthcare | Maintains: Outperform | $500 → $540 | $544.41 | -0.81% | 13 | Jan 28, 2026 | |
| EHAB Enhabit | Upgrades: Outperform | $14 | $13.61 | +2.87% | 3 | Jan 22, 2026 | |
| GRDN Guardian Pharmacy Services | Initiates: Outperform | $30 | $34.76 | -13.69% | 1 | Oct 10, 2025 | |
| CNC Centene | Maintains: Outperform | $51 → $43 | $44.99 | -4.42% | 19 | Jul 28, 2025 | |
| HUM Humana | Maintains: Outperform | $300 → $310 | $183.11 | +69.30% | 13 | May 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $400 → $375 | $284.74 | +31.70% | 11 | Jan 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $37 | $33.54 | +10.32% | 6 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $165 → $168 | $212.05 | -20.77% | 8 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $140 → $145 | $105.68 | +37.21% | 10 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4.5 → $5 | $3.43 | +45.77% | 10 | Jul 25, 2024 |
PACS Group
Mar 4, 2026
Maintains: Outperform
Price Target: $40 → $42
Current: $36.35
Upside: +15.54%
Teladoc Health
Mar 3, 2026
Maintains: Outperform
Price Target: $12 → $7
Current: $5.13
Upside: +36.45%
Evolent Health
Mar 2, 2026
Maintains: Outperform
Price Target: $12 → $6
Current: $3.55
Upside: +69.01%
Chemed
Feb 27, 2026
Maintains: Outperform
Price Target: $580 → $500
Current: $410.99
Upside: +21.66%
UnitedHealth Group
Jan 28, 2026
Maintains: Outperform
Price Target: $415 → $385
Current: $291.96
Upside: +31.87%
HCA Healthcare
Jan 28, 2026
Maintains: Outperform
Price Target: $500 → $540
Current: $544.41
Upside: -0.81%
Enhabit
Jan 22, 2026
Upgrades: Outperform
Price Target: $14
Current: $13.61
Upside: +2.87%
Guardian Pharmacy Services
Oct 10, 2025
Initiates: Outperform
Price Target: $30
Current: $34.76
Upside: -13.69%
Centene
Jul 28, 2025
Maintains: Outperform
Price Target: $51 → $43
Current: $44.99
Upside: -4.42%
Humana
May 1, 2025
Maintains: Outperform
Price Target: $300 → $310
Current: $183.11
Upside: +69.30%
Jan 31, 2025
Maintains: Outperform
Price Target: $400 → $375
Current: $284.74
Upside: +31.70%
Nov 8, 2024
Maintains: Outperform
Price Target: $34 → $37
Current: $33.54
Upside: +10.32%
Oct 25, 2024
Maintains: Outperform
Price Target: $165 → $168
Current: $212.05
Upside: -20.77%
Sep 23, 2024
Maintains: Outperform
Price Target: $140 → $145
Current: $105.68
Upside: +37.21%
Jul 25, 2024
Maintains: Outperform
Price Target: $4.5 → $5
Current: $3.43
Upside: +45.77%